Health Care & Life Sciences » Pharmaceuticals | Merrimack Pharmaceuticals Inc.

Merrimack Pharmaceuticals Inc. | Ownership

Companies that own Merrimack Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
BVF Partners LP
1,110,588
8.32%
1,110,588
0.44%
06/30/2018
Newtyn Management LLC
633,297
4.75%
492,440
0.67%
06/30/2018
The Vanguard Group, Inc.
551,122
4.13%
-26,779
0%
06/30/2018
Rubric Capital Management LP
476,164
3.57%
0
0.28%
06/30/2018
Dimensional Fund Advisors LP
468,377
3.51%
98,395
0%
06/30/2018
TIAA-CREF Investment Management LLC
402,457
3.02%
-146,424
0%
06/30/2018
Wittenberg Investment Management, Inc.
253,752
1.9%
130,441
0.57%
06/30/2018
BlackRock Fund Advisors
250,344
1.88%
-501,736
0%
06/30/2018
Connor, Clark & Lunn Investment Management Ltd.
174,774
1.31%
31,509
0.01%
06/30/2018
Millennium Management LLC
170,906
1.28%
39,402
0%
06/30/2018

About Merrimack Pharmaceuticals

View Profile
Address
One Broadway
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.merrimackpharma.com
Updated 07/08/2019
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.